Evidence map›Paper›PMID 40773050›Full record

ArticleBrain tumor pathology2025

Association between autologous formalin-fixed tumor vaccine (AFTV) therapy, molecular pathological markers, and survival outcomes in glioblastoma.

Shunichi Koriyama, Yoshihiro Muragaki, Masayuki Nitta, Takashi Maruyama, Taiichi Saito, Shunsuke Tsuzuki, Tatsuya Kobayashi, Buntou Ro, Takashi Komori, Kenta Masui and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain tumor pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shunichi KoriyamaDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Yoshihiro MuragakiDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan. muragaki@people.kobe-u.ac.jp.ORCID http://orcid.org/0000-0001-8336-5328
Masayuki NittaDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Takashi MaruyamaDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Taiichi SaitoDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Shunsuke TsuzukiDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Tatsuya KobayashiDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Buntou RoDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Takashi KomoriDepartment of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo Metropolitan Hospital Organization, Tokyo, Japan.
Kenta MasuiDepartment of Pathology, Tokyo Women's Medical University, Tokyo, Japan.
Takakazu KawamataDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is a primary brain tumor, characterized by rapid progression, high recurrence rates, and resistance to standard therapies. Current treatment modalities provide limited survival benefits, highlighting the need for novel therapeutic strategies. This retrospective study evaluated the efficacy of autologous formalin-fixed tumor vaccine (AFTV) in 375 patients with newly diagnosed GBM. Patients receiving AFTV therapy (n = 164) showed significantly improved progression-free survival (PFS; 14.0 months vs. 8.7 months, p = 0.03) and overall survival (OS; 32.0 months vs. 21.9 months, p < 0.01) compared with the non-AFTV group (n = 211). Subgroup analyses revealed that AFTV therapy was particularly effective in patients with wild-type IDH tumors and those negative for PD-L1 and p53 expression. In contrast, patients whose tumors were positive for both PD-L1 and p53 exhibited significantly poorer outcomes. These findings suggest that the combination of PD-L1 and p53 status may serve as a useful biomarker for predicting AFTV responsiveness, reflecting the influence of the immunosuppressive tumor microenvironment on treatment efficacy. These findings establish AFTV as a promising treatment option for GBM and highlight the importance of molecular profiling in treatment selection. Future studies should explore combining AFTV with immune checkpoint inhibitors to enhance efficacy in PD-L1-positive cases.

Indexed as

Biomarkers, TumorBrain NeoplasmsCancer VaccinesGlioblastomaAdultAgedAged, 80 and overB7-H1 AntigenFemaleFormaldehydeHumansMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesTreatment OutcomeB7-H1 AntigenBiomarkers, TumorCancer VaccinesCD274 protein, humanFormaldehydeTP53 protein, humanTumor Suppressor Protein p53Autologous formalin-fixed tumor vaccineGlioblastomaIDH mutationp53 expressionProgrammed death-ligand 1

Identifiers

PMID40773050
PMCPMC12408717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.